Table 1.
Patients demographics and characteristics at diagnosis
| Combined data | Study A: 2 sunitinib cycles | Study B: 3 sunitinib cycles | |
| Number of patients | 52 | 19 (37%) | 33 (63%) |
| Age | 60.5 (range 37–78) | 51 (range 37–78) | 62 (range 44–76) |
| Gender, n (%) | |||
| Male | 41 (77) | 15 (79) | 26 (79) |
| Female | 11 (23) | 4 (21) | 7 (21) |
| MSKCC prognostic risk, n (%) | |||
| Intermediate | 35 (66) | 18 (95) | 17 (52) |
| Poor | 17 (33) | 1 (5) | 16 (48) |
| Number of metastatic sites, n (%) | |||
| 0 | 0 | 0 | 0 |
| 1 | 15 (29) | 4 (21) | 11 (33) |
| 2 | 17 (33) | 6 (32) | 11 (33) |
| 3+ | 20 (38) | 9 (47) | 11 (33) |
| Sites of metastatic disease on CT, n (%) | |||
| Lung | 46 (88) | 18 (95) | 28 (84) |
| Bone | 16 (31) | 3 (15) | 13 (33) |
| Lymph node | 26 (50) | 9 (47) | 17 (52) |
| Liver | 7 (13) | 3 (15) | 4 (12) |
| Other | 12 (27) | 4 (21) | 8 (24) |
| Primary tumor size [longest diameter (median in cm)] | 9.45 (4.2–23.2) | 10.3 (6.8–23.2) | 9.9 (4.2–18.7) |
| Histology prior to surgery, n (%) | |||
| Clear cell | 52 | 19 | 33 |
| Other | 0 | 0 | 0 |
CT, computed tomography scan; MSKCC, Memorial Sloan Kettering Cancer Center.